Comparative Pharmacology
Head-to-head clinical analysis: ATORVALIQ versus ROSUVASTATIN CALCIUM.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ATORVALIQ versus ROSUVASTATIN CALCIUM.
ATORVALIQ vs ROSUVASTATIN CALCIUM
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
ATORVALIQ is a combination of atorvastatin and amlodipine. Atorvastatin is an HMG-CoA reductase inhibitor that decreases cholesterol synthesis in the liver. Amlodipine is a calcium channel blocker that inhibits calcium ion influx across cardiac and vascular smooth muscle, causing vasodilation.
Rosuvastatin is a competitive inhibitor of HMG-CoA reductase, the rate-limiting enzyme in cholesterol biosynthesis. This reduces hepatic cholesterol synthesis, upregulates LDL receptors, and enhances clearance of LDL from plasma.
10-80 mg orally once daily. Starting dose 10-20 mg. Max dose 80 mg.
Oral, 5-40 mg once daily, starting at 5-10 mg, titrated based on LDL-C response, maximum 40 mg/day.
None Documented
None Documented
The terminal elimination half-life of atorvastatin is approximately 14 hours; however, its active metabolites have a half-life of 20-30 hours, allowing for once-daily dosing.
Terminal elimination half-life is approximately 19 hours, which supports once-daily dosing and allows for sustained HMG-CoA reductase inhibition.
Atorvastatin is primarily eliminated via biliary/fecal excretion (approximately 70% as metabolites), with renal excretion accounting for less than 2% of the administered dose.
Approximately 90% of the absorbed dose is excreted in feces via biliary elimination, with the remaining 10% excreted renally as unchanged drug and metabolites. Unchanged rosuvastatin accounts for about 5% of the dose in urine.
Category C
Category D/X
Statin
Statin